SAB Biotherapeutics, Inc.SABSNASDAQ
Loading
Asset Growth AcceleratingAccelerating
Percentile Rank100
5Y CAGR+6.3%
Studio
Year-over-Year Change

Year-over-year total asset growth rate

5Y CAGR
+6.3%/yr
Long-term compound
Percentile
P100
Near historical high
vs 5Y Ago
1.4x
Solid growth
Streak
1 yr
Consecutive growthAccelerating
PeriodValue
2025291.01%
2024-47.35%
202364.90%
2022-37.26%
202143.52%
2020214.04%
20190.00%